BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12583555)

  • 1. Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
    Bar Sela G; Tsalic M; Gaitini D; Steiner M; Haim N
    J Chemother; 2002 Dec; 14(6):623-6. PubMed ID: 12583555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
    Kelsen D; Atiq OT; Saltz L; Niedzwiecki D; Ginn D; Chapman D; Heelan R; Lightdale C; Vinciguerra V; Brennan M
    J Clin Oncol; 1992 Apr; 10(4):541-8. PubMed ID: 1548519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
    Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
    Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
    Webb A; Cunningham D; Scarffe JH; Harper P; Norman A; Joffe JK; Hughes M; Mansi J; Findlay M; Hill A; Oates J; Nicolson M; Hickish T; O'Brien M; Iveson T; Watson M; Underhill C; Wardley A; Meehan M
    J Clin Oncol; 1997 Jan; 15(1):261-7. PubMed ID: 8996151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of gastric adenocarcinoma with the combination of etoposide, adriamycin and cisplatin (EAP): comparison between two schedules.
    Haim N; Tsalik M; Robinson E
    Oncology; 1994; 51(1):102-7. PubMed ID: 8265093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
    Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
    J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of advanced gastric cancer.
    Wils J
    Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the treatment of gastric carcinoma.
    Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.
    Lerner A; Gonin R; Steele GD; Mayer RJ
    J Clin Oncol; 1992 Apr; 10(4):536-40. PubMed ID: 1548518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
    Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
    Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
    Yeh KH; Cheng AL; Chen YC; Chen BR; Lee WJ; Lin JT; Lee PH; Chang KJ; Wang CH; Wang TH
    J Formos Med Assoc; 1994 Jan; 93(1):20-4. PubMed ID: 7915575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer.
    Scarpellini M; Tononi A; Pasquini E; Oliverio G; Fattori PP; Gianni L; Desiderio F; Nicolini M; Ravaioli A
    J Chemother; 1994 Jun; 6(3):211-5. PubMed ID: 7983505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
    Cocconi G; Carlini P; Gamboni A; Gasperoni S; RodinĂ² C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
    Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
    Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
    Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful treatment of two patients with advanced gastric cancer by neoadjuvant chemotherapy with EAP regimen].
    Matsumura T; Ohnoshi T; Ueoka H; Kiura K; Tabata M; Genba K; Chikamori M; Ikubo S; Matsuo K; Kimura I
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):261-4. PubMed ID: 8311499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial.
    Kulig J; Kolodziejczyk P; Sierzega M; Bobrzynski L; Jedrys J; Popiela T; Dadan J; Drews M; Jeziorski A; Krawczyk M; Starzynska T; Wallner G
    Oncology; 2010; 78(1):54-61. PubMed ID: 20215786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
    Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule.
    Gebbia V; Valenza R; Testa A; Sciume C; Longo A; Cipolla C; Borsellino N; Leo P; Latteri M; Florena M
    J Cancer Res Clin Oncol; 1994; 120(9):550-2. PubMed ID: 8045920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.